Search results
Results From The WOW.Com Content Network
June 17, 2024 at 8:37 AM. (Reuters) -Japanese drugmaker Takeda said on Monday its experimental drug being tested for two epileptic disorders failed to reduce frequency of seizures in patients ...
In July, Takeda had said the study had been halted due to futility as it was unlikely to meet its goal. It also withdrew its application for marketing authorization in the European Union in 2022.
Takeda Midosuji Building, headquarters of Takeda Pharmaceutical Company, in Chuo-ku, Osaka, Japan. Takeda Pharmaceuticals was founded in 1781, and was incorporated on January 29, 1925. One of the firm's mainstay drugs is Actos (pioglitazone), a compound in the thiazolidinedione class of drugs used in the treatment of type 2 diabetes. It was ...
Peginesatide [2] ( INN / USAN, trade name Omontys, formerly Hematide ), developed by Affymax and Takeda, is an erythropoietic agent, a functional analog of erythropoietin . It was approved by the U.S. Food and Drug Administration for treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis.
Vonoprazan, sold under the brand name Voquezna among others, is a first-in-class potassium-competitive acid blocker medication. Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.
Takeda expects Adzynma will be commercially available in December 2023, and pricing will be disclosed at that time, the president of its US business unit, Julie Kim, told Reuters.
Vedolizumab. Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Millennium Pharmaceuticals, Inc. for the treatment of ulcerative colitis and Crohn's disease. [5] It binds to integrin α 4 β 7 ( LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7 ...
TOKYO (Reuters) -Japan's biggest drugmaker Takeda Pharmaceutical on Thursday slashed its full-year profit forecast by 36% as it contends with disappointments in its development pipeline and the ...